353 related articles for article (PubMed ID: 37142441)
1. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.
Muniyandi A; Hartman GD; Song Y; Mijit M; Kelley MR; Corson TW
J Pharmacol Exp Ther; 2023 Jul; 386(1):15-25. PubMed ID: 37142441
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy.
Hartman GD; Lambert-Cheatham NA; Kelley MR; Corson TW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638620
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
5. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
6. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
Nair AA; Finn AP; Sternberg P
Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
[TBL] [Abstract][Full Text] [Related]
7. Applications of nanomaterials in anti-VEGF treatment for ophthalmic diseases.
Teng L; Sun Y; Teng S; Hui P
J Biomed Mater Res A; 2024 Feb; 112(2):296-306. PubMed ID: 37850566
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for the treatment of ocular neovascularization.
Bradley J; Ju M; Robinson GS
Angiogenesis; 2007; 10(2):141-8. PubMed ID: 17372853
[TBL] [Abstract][Full Text] [Related]
10. RhoB antibody alters retinal vascularization in models of murine retinopathy.
Almonte-Baldonado R; Bravo-Nuevo A; Gerald D; Benjamin LE; Prendergast GC; Laury-Kleintop LD
J Cell Biochem; 2019 Jun; 120(6):9381-9391. PubMed ID: 30536763
[TBL] [Abstract][Full Text] [Related]
11. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC
BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
Joussen AM
Dtsch Med Wochenschr; 2007 Jun; 132(23):1268-72. PubMed ID: 17541869
[TBL] [Abstract][Full Text] [Related]
13. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation.
Hu WH; Zhang XY; Leung KW; Duan R; Dong TT; Qin QW; Tsim KW
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742898
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor in eye disease.
Penn JS; Madan A; Caldwell RB; Bartoli M; Caldwell RW; Hartnett ME
Prog Retin Eye Res; 2008 Jul; 27(4):331-71. PubMed ID: 18653375
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
17. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab.
Khan M; Aziz AA; Shafi NA; Abbas T; Khanani AM
Cells; 2020 Aug; 9(8):. PubMed ID: 32785136
[TBL] [Abstract][Full Text] [Related]
18. TNF-α signaling regulates RUNX1 function in endothelial cells.
Whitmore HAB; Amarnani D; O'Hare M; Delgado-Tirado S; Gonzalez-Buendia L; An M; Pedron J; Bushweller JH; Arboleda-Velasquez JF; Kim LA
FASEB J; 2021 Feb; 35(2):e21155. PubMed ID: 33135824
[TBL] [Abstract][Full Text] [Related]
19. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?
Lim LS; Cheung CMG; Mitchell P; Wong TY
Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670
[No Abstract] [Full Text] [Related]
20. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
